Derived from the metastasized neuroblastoma of a young human
female, the SK-N-SH cell line is one of the primary in vitro models for brain cancer drug development and testing of
novel immunotherapies. With neurite outgrowths and modulated differentiation,
SK-N-SH complement dopamine-beta-hydroxylase expression with a physiology that
closely follows that of live neuroblastoma tissue in vivo. With cancer-specific transfection
reagents, research involving the screening of siRNA sequences can show how
RNA interference technology could be used to combat cancer proliferation even
after metastasis.
The SK-N-SH cell line was established in 1970 from the bone marrow metastasis of a 4-year-old female with neuroblastoma. SK-N-SH cells exhibit an epithelial morphology and adherent cultural properties. SK-N-SH is capable of differentiating and exhibiting neurite outgrowths. This hyperdiploid cell line has a modal chromosome number of 47 and is genetically female with two X chromosomes. SK-N-SH cells express blood type A and Rh+ , as well as produce high levels of dopamine-beta-hydroxylase. Pediatric brain cancer is one of the leading causes of cancer-related deaths in children under 20 years old, and neuroblastoma cell lines like SK-N-SH are valuable tools in preclinical research that allow scientists to develop new drugs and treatments. A pre-optimized SK-N-SH transfection reagent to transfect SK-N-SH cells and conduct brain cancer research is commercially available from Altogen Biosystems . SK-N-SH cells can also be used to study neural pathways. Past studies h...
Comments
Post a Comment